Literature DB >> 8461063

Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels.

B A Larsen1, B G Nordestgaard, S Stender, K Kjeldsen.   

Abstract

The aim was to examine the effect of testosterone on atherogenesis in cholesterol-fed, castrated male rabbits not mediated via different plasma cholesterol levels. The rabbits in the testosterone group (n = 19) and in the placebo group (n = 17) were injected intramuscularly twice weekly for 17 weeks with 25 mg testosterone enantate and placebo, respectively, reaching plasma testosterone levels of 50-150 nmol/l in the testosterone group. No effect of testosterone on liver function or body weight was detected, but at week 15 mean blood pressure was 75 +/- 2 mmHg (mean +/- S.E.) in the testosterone group compared with 69 +/- 2 mmHg in the placebo group (P < 0.05). To reduce variation in plasma cholesterol between the two groups, the amount of cholesterol fed to each rabbit was adjusted on the basis of weekly determinations of plasma cholesterol; the mean plasma cholesterol levels during the 17 weeks were 20.9 +/- 1.0 and 20.4 +/- 0.9 mmol/l for the placebo and testosterone groups. In the intima-inner medias of the aortic arch, the thoracic and the abdominal aorta there were no consistent significant differences in aortic cholesterol content, expressed either as nmol/cm2 or nmol/mg protein, between the two groups. However, the aortic cholesterol content tended to be lower in the testosterone group than in the placebo group. These findings suggest that in cholesterol-fed, castrated male rabbits, testosterone does not promote atherogenesis by an effect directly on the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461063     DOI: 10.1016/0021-9150(93)90053-w

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries.

Authors:  H Teoh; A Quan; S W Leung; R Y Man
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice.

Authors:  Tracy Henriques; Xuan Zhang; Frederique B Yiannikouris; Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

3.  Evaluation of vascular reactivity of young male hypogonadotrophic hypogonadism patients.

Authors:  Ferhat Deniz; Necip Ermiş; Alper Kepez; Bariş Türk; Murat Akkoyunlu; Batuhan Kara; Mustafa Kutlu
Journal:  Int J Cardiovasc Imaging       Date:  2009-09-12       Impact factor: 2.357

4.  Chronic Exercise Reduces CETP and Mesterolone Treatment Counteracts Exercise Benefits on Plasma Lipoproteins Profile: Studies in Transgenic Mice.

Authors:  Andrea Camargo Casquero; Jairo Augusto Berti; Laura Lauand Sampaio Teixeira; Helena Coutinho Franco de Oliveira
Journal:  Lipids       Date:  2017-10-20       Impact factor: 1.880

Review 5.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

Review 6.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

7.  Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Authors:  Jinsheng Zhao; Shimiao Zhu; Libin Sun; Fanzheng Meng; Lin Zhao; Yusheng Zhao; Hao Tian; Ping Li; Yuanjie Niu
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

Review 8.  Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?

Authors:  Dheeraj Kapoor; T Hugh Jones
Journal:  Drugs Aging       Date:  2008       Impact factor: 4.271

Review 9.  Androgen therapy and atherosclerotic cardiovascular disease.

Authors:  K-C Y McGrath; L S McRobb; A K Heather
Journal:  Vasc Health Risk Manag       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.